全文获取类型
收费全文 | 51220篇 |
免费 | 4363篇 |
国内免费 | 634篇 |
专业分类
耳鼻咽喉 | 208篇 |
儿科学 | 459篇 |
妇产科学 | 998篇 |
基础医学 | 4524篇 |
口腔科学 | 219篇 |
临床医学 | 5841篇 |
内科学 | 3555篇 |
皮肤病学 | 253篇 |
神经病学 | 522篇 |
特种医学 | 2855篇 |
外科学 | 7433篇 |
综合类 | 5531篇 |
一般理论 | 2篇 |
预防医学 | 3150篇 |
眼科学 | 72篇 |
药学 | 3523篇 |
20篇 | |
中国医学 | 787篇 |
肿瘤学 | 16265篇 |
出版年
2024年 | 29篇 |
2023年 | 759篇 |
2022年 | 1650篇 |
2021年 | 2368篇 |
2020年 | 2024篇 |
2019年 | 2251篇 |
2018年 | 2455篇 |
2017年 | 2158篇 |
2016年 | 1856篇 |
2015年 | 1976篇 |
2014年 | 4191篇 |
2013年 | 3730篇 |
2012年 | 3168篇 |
2011年 | 3411篇 |
2010年 | 2532篇 |
2009年 | 2776篇 |
2008年 | 3025篇 |
2007年 | 2666篇 |
2006年 | 2125篇 |
2005年 | 1575篇 |
2004年 | 1346篇 |
2003年 | 1021篇 |
2002年 | 782篇 |
2001年 | 764篇 |
2000年 | 677篇 |
1999年 | 588篇 |
1998年 | 501篇 |
1997年 | 476篇 |
1996年 | 368篇 |
1995年 | 366篇 |
1994年 | 342篇 |
1993年 | 238篇 |
1992年 | 175篇 |
1991年 | 149篇 |
1990年 | 116篇 |
1989年 | 146篇 |
1988年 | 96篇 |
1987年 | 91篇 |
1986年 | 67篇 |
1985年 | 170篇 |
1984年 | 167篇 |
1983年 | 116篇 |
1982年 | 170篇 |
1981年 | 130篇 |
1980年 | 119篇 |
1979年 | 96篇 |
1978年 | 59篇 |
1977年 | 37篇 |
1976年 | 37篇 |
1975年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
4.
Background: Breast cancer (BC) is the most common malignant tumor in women, and its morbidity and mortality are
increasing each year, due to the lack of specific clinical symptoms in the early stage of BC, and the lack of diagnostic
methods for early breast cancer. Therefore, identifying an effective diagnostic method for early BC has become urgent.
Materials and Methods: Breast lesions with a histological diagnosis that were examined by ultrasonic elastography
(UE) in our department from June 2020 to December 2021 were reviewed. qRT-PCR was performed to measure
the expression levels of miR-144-5p and miR-26b-5p in the plasma of patients with BC. The receiver operating characteristics (ROC) curve and area under the curve (AUC) were used to investigate the potential diagnostic value of miR-
144-5p, miR-26b-5p and the elastographic score in BC. Results: The ultrasonic elastography score(UES) was found to
be significantly upregulated in BC compared with that in benign breast lesions, and the AUC, sensitivity and specificity
were 0.809, 0.717 and 0.806 for distinguishing BC from benign breast lesions, respectively. miR-144-5p and miR-26b-
5p were found to be upregulated in the plasma of BC patients, and miR-144-5p+miR-26b-5p had 0.781 sensitivity and
0.780 specificity for the diagnosis of BC. Furthermore, we found that the diagnostic performance of miR-144-5p and
miR-26b-5p combined with UES for BC had 0.913 sensitivity and 0.890 specificity. Conclusions: The combination of
plasma miR-144-5p, miR-26b-5p and UES has a very high clinical application value for the early detection of BC. 相似文献
5.
6.
7.
目的 根据乳腺癌内分泌治疗患者的症状特征,编制适用于我国乳腺癌内分泌治疗患者的症状评估量表,并检验其信效度。方法 在文献回顾及参照现有症状评估量表的基础上编制量表初始条目池;通过2轮德尔菲专家函询,形成初始版量表;通过对11例患者的认知性访谈,对量表条目进一步修订,形成临床测试版量表。便利选取2020年7月—9月在浙江省某三级甲等肿瘤医院门诊或住院的325例乳腺癌内分泌治疗患者进行问卷调查,检验量表信效度。 结果 形成的最终版乳腺癌内分泌治疗患者症状评估量表包括33个条目,探索性因子分析提取7个公因子,累计方差贡献率为68.76%;各条目内容效度指数为0.78~1.00,量表内容效度指数为0.91;内在相关性检验结果显示,量表各维度与总量表相关系数为0.58~0.79(P<0.05);维度间相关系数为0.26~0.52(P<0.05);总量表Cronbach’s α系数为0.94,重测信度为0.95,折半信度为0.84。结论 编制的乳腺癌内分泌治疗患者症状评估量表具有良好的信效度,适用于相关人群的症状测评。 相似文献
8.
9.
《Transfusion and apheresis science》2022,61(4):103488
The COVID-19 pandemic caused by the SARS-CoV-2 virus has significantly disrupted and burdened the diagnostic workup and delivery of care, including transfusion, to cancer patients across the globe. Furthermore, cancer patients suffering from solid tumors or hematologic malignancies were more prone to the infection and had higher morbidity and mortality than the rest of the population. Major signaling pathways have been identified at the intersection of SARS-CoV-2 and cancer cells, often leading to tumor progression or alteration of the tumor response to therapy. The reactivation of oncogenic viruses has also been alluded to in the context and following COVID-19. Paradoxically, certain tumors responded better following the profound infection-induced immune modulation. Unveiling the mechanisms of the virus-tumor cell interactions will lead to a better understanding of the pathophysiology of both cancer progression and virus propagation. It would be challenging to monitor, through the different cancer registries, retrospectively, the response of patients who have been previously exposed to the virus in contrast to those who have not contracted the infection. 相似文献
10.